A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.

Thumbnail Image

Files

Tiu_2020_LOauthor manuscript_clean.pdf (933.9 KB)

Embargo End Date

ICR Authors

Tiu, Crescens
 Yap, Christina
 Banerji, Udai
 Minchom, Anna
 De Bono, Johann
 Lopez, Juanita

Authors

Tiu, C
Shinde, R
Yap, C
Rao Baikady, B
Banerji, U
Minchom, AR
de Bono, JS
Lopez, JS

Document Type

Journal Article

Date

2020-07-01

Date Accepted

2020-05-27

Abstract

Citation

The Lancet. Oncology, 2020, 21 (7), pp. 889 - 891

DOI

10.1016/s1470-2045(20)30339-9

URI

https://repository.icr.ac.uk/handle/internal/3801

Rights

https://www.rioxx.net/licenses/under-embargo-all-rights-reserved

Source Title

Publisher

ELSEVIER SCIENCE INC

ISSN

1470-2045

eISSN

1474-5488

Collections

Cancer Therapeutics
Clinical Studies

Research Team

Medicine (de Bono Prostate)
Clinical Pharmacology – Adaptive Therapy
Clinical Trials & Statistics Unit
Prostate Cancer Targeted Therapy Group

Notes